Drugs / Triciribine
Triciribine
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00642031 | Aug 2006 → Oct 2012 | leukemia | Prescient Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00363454 | Apr 2006 → Sep 2010 | cancer | Prescient Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01690468 | Sep 2014 → Dec 2019 | ovarian cancer | Prescient Therapeutics, Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01697293 | Jan 2012 → Jun 2020 | Her2-receptor negative breast cancer, breast adenocarcinoma, estrogen-receptor positive breast cancer, female breast carcinoma | Prescient Therapeutics, Ltd. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05826964 | Jun 2023 → Jul 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | University of Miami | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triciribine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01690468 ↗ |
| Known as | AKT inhibitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05826964 ↗ |
| Known as | Triciribine Phosphate Monohydrate | “Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer” NCT00363454 ↗1“Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies” NCT00642031 ↗ |
| Known as | VD-0002 | “Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer” NCT00363454 ↗ |
| Action | Inhibit | “AKT inhibitor” NCT01690468 ↗ |
| Route | Intravenous | “To be given as a 60 minute IV infusion.” NCT01690468 ↗ |